Of note, glasdegib, an inhibitor of the smoothened multi-transmembrane (SMO), a component of the Hedgehog pathway, combined with LDAC, which was approved for newly-diagnosed AML in the elderly, who are ineligible to receive standard induction chemotherapy, has shown an increase in the OS rate (8.8 months versus 4.9 months in LDAC only) (92, 93). This evidence concerns the gene SMO and acute myeloid leukemia.